Exploring Keratinocyte Carcinoma Models for Preclinical Treatment Evaluation

Pharmacology, Toxicology and Pharmaceutical Science

• Carcinoma 100%
• Skin Carcinoma 50%
• Anti-Inflammatory Drug 41%
• Basal Cell Carcinoma 41%
• Mouse Model 33%
• Resiquimod 33%
• Inflammation 16%
• Wound Healing 16%
• Tumor Model 16%
• Imiquimod 16%
• Preclinical Study 8%
• Sustained Release 8%
• Drug Development 8%
• Flow Cytometry 8%
• Ultraviolet Radiation 8%
• Genetically Engineered Mouse Strain 8%
• Immune Checkpoint Inhibitor 8%
• RNA-Sequencing 8%
• Malignant Neoplasm 8%
• Immunotherapy 8%
• Prevalence 8%
• Neoplasm 8%
• Toll Like Receptor 7 8%
• Arginase 1 8%

Immunology and Microbiology

• Keratinocyte 100%
• Squamous Cell 46%
• Basal Cell 38%
• Mouse Model 30%
• Resiquimod 30%
• Immune Response 23%
• Inflammation Response 15%
• Macrophage 15%
• Wound Healing 15%
• Immunity 15%
• Preclinical Study 15%
• Imiquimod 15%
• Agonist 7%
• Prevalence 7%
• Upregulation 7%
• Cell Population 7%
• Immunocompetent Cell 7%
• Immunotherapy 7%
• RNA Sequence 7%
• Tumor Cell 7%
• Ultraviolet Radiation 7%
• Genetically Engineered Mouse Strain 7%
• Sustained Drug Release 7%
• Toll-Like Receptor 7%

Keyphrases

• Preclinical Therapy 100%
• Gel Treatment 8%
• Imiquimod Cream 8%
• Topical Imiquimod 8%
• Mouse Skin 8%
• Polarized Macrophages 8%